SCHEMBL28114911

SCHEMBL28114911

C[CH]c1ccc(O)c([N+](=O)[O-])c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH5A1 P51649 1/20 0.71
ABAT P80404 1/20 0.71
EGFR P00533 2/20 0.59
ALDH1A1 P00352 6/20 0.56
MAPK1 P28482 3/20 0.56
HPGD P15428 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
TP53 P04637 1/20 0.56
TSHR P16473 1/20 0.56
GPR35 Q9HC97 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
ALOX15 P16050 1/20 0.55
HSD17B10 Q99714 1/20 0.55
GSK3B P49841 2/20 0.52
MAPT P10636 9/20 0.52
KMT2A Q03164 7/20 0.52
MEN1 O00255 6/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28601429 0.86 ALDH5A1 (0.67) ALDH5A1ABATEGFRALDH1A1MAPK1
SCHEMBL244093 0.83 ALDH5A1 (1.00) ALDH5A1ABATEGFRALDH1A1MAPK1
Iodomethane SCHEMBL27504663 0.82 ALDH5A1 (0.90) ALDH5A1ABATEGFRALDH1A1MAPK1
SCHEMBL5661502 0.81 ALDH5A1 (0.71) ALDH5A1ABATEGFRALDH1A1MAPK1
SCHEMBL10920512 0.80 EGFR (0.73) ALDH5A1ABATEGFRALDH1A1MAPK1
SCHEMBL10920508 0.80 EGFR (0.73) ALDH5A1ABATEGFRALDH1A1MAPK1
SCHEMBL27932094 0.79 ALDH1A1 (0.56) ALDH5A1ABATALDH1A1MAPK1SMN1; SMN2
SCHEMBL29737122 0.79 ALDH5A1 (0.67) ALDH5A1ABATEGFRALDH1A1MAPK1
SCHEMBL11239202 0.79 EGFR (0.72) ALDH5A1ABATEGFRALDH1A1MAPK1
SCHEMBL11851919 0.79 EGFR (0.72) ALDH5A1ABATEGFRALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106132422-A Adoptive cell therapy using agonists of retinoic acid receptor-associated orphan receptor gamma & related therapeutic methods 莱斯拉公司 2016-11-16 CN disclosed